Lumicitabine, formerly known as ALS-8176, is an orally bioavailable prodrug of the novel RSV replication inhibitor ALS-8112. In nonclinical studies, ALS-008112 enters various types of epithelial cells in the respiratory tract and is subsequently phosphorylated to form an intracellular nucleoside triphosphate with a half-life of approximately 29 hours. The nucleoside triphosphate analogue inhibits RSV replication by means of chain termination. References: Fearns R, Deval J. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase. Antiviral Res. 2016 Aug 26. pii: S0166-3542(16)30352-7. doi: 10.1016/j.antiviral.2016.08.006. [Epub ahead of print] Review. PubMed PMID: 27575793.

纯度：≥98%

CAS：1445385-02-3